CSHS WWW HOME | MS EXCHANGE LOG ON | PULSE ARCHIVES
Medical Staff Pulse is
a Publication of the Chief of Staff
MEC Update on Gadolinium Contrast Media

MEC Approves Policy for Administration of Gadolinium Based Contrast Media

To ensure the safety and uniformity of care for patients with moderate to significant renal disease who are to receive gadolinium, the Medical Executive Committee (MEC) has approved a new policy and consent form, "Administration of Gadolinium Based Contrast Media in Patients with Moderate to Significant Renal Disease."

The policy states that the Department of Imaging recognizes the rare complication of life-threatening Nephrogenic Fibrosing Dermopathy or Nephrogenic Systemic Fibrosis (NFD/NSF) in patients with renal disease who receive gadolinium contrast media.

Under the new policy, approved by the MEC on March 27, 2007, the following procedure has been implemented:

  • The patient will be screened to determine of they have the potential for moderate to severe renal failure. If it is determined that there is a potential for moderate to severe renal failure, then a creatinine and GFR will be obtained.
  • If the creatinine is > 2.5 mg/dL and/or if GFR is less than 60 mL/minute, a radiologist will be notified to consider medical necessity, alternatives, and/or to consult with the referring M.D.
  • If it is determined that contrast will be given to a patient with renal disease, a single dose of .1 mmol/kg should not be exceeded unless otherwise directed by an Imaging physician.
  • The patient will be asked to sign a consent form indicating the risks associated with receiving gadolinium.
  • As recommended by the FDA, renal dialysis following the MRI should be considered in patients who are on renal dialysis.